Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic ...

Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is ...

A woman with metastatic lung adenocarcinoma harboring a ROS1 rearrangement initially showed a response to treatment with crizotinib, but the disease ultimately progressed. In her resistant tumors, we ...

In late June 2026, Nuvation Bio announced that partner Eisai’s Marketing Authorisation Application for taletrectinib in ...

A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Nuvation Bio Inc.’s (NASDAQ:NUVB) Ibtrozi (taletrectinib) for adult patients with locally advanced or metastatic ROS1-positive (ROS1+) ...

Immunohistochemistry (IHC) is an effective tool that can be used for identifying proto-oncogene 1 receptor tyrosine kinase (ROS1) gene rearrangements and screening patients for the administration of ...

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotech firm Nuvalent said Tuesday that new data indicate its targeted drug zidesamtinib could help patients with a rare ...

An expert discusses the evolution of ROS1 testing in non-small cell lung cancer, highlighting the shift from FISH-based methods to comprehensive next-generation sequencing of both tissue and plasma, ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...

Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...